Threshold Pharmaceuticals To Stop Enrollment In Clinical Trial

Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), announced that, as part of a planned interim analysis, it would stop enrollment in a Phase 2 clinical trial evaluating the efficacy and safety of glufosfamide in patients with recurrent, sensitive small cell lung cancer. The clinical trial utilized a two stage design to ensure there would be an adequate response rate to justify complete enrollment. [click link for full article]

More: continued here

Filed under: Lung Cancer on October 20th, 2007